Company Information

WOCKHARDT LTD.

NSE : WOCKPHARMABSE : 532300ISIN CODE : INE049B01025Industry : Pharmaceuticals & DrugsHouse : Wockhardt
BSE552.603.35 (+0.61 %)
PREV CLOSE ( ) 549.25
OPEN PRICE ( ) 549.00
BID PRICE (QTY) 549.50 (10)
OFFER PRICE (QTY) 552.80 (2)
VOLUME 16729
TODAY'S LOW / HIGH ( )549.00 560.00
52 WK LOW / HIGH ( )165.2 630
NSE549.20-0.05 (-0.01 %)
PREV CLOSE( ) 549.25
OPEN PRICE ( ) 550.00
BID PRICE (QTY) 549.20 (237)
OFFER PRICE (QTY) 550.00 (9)
VOLUME 105429
TODAY'S LOW / HIGH( ) 543.00 559.90
52 WK LOW / HIGH ( )165 630
ChairmanHabil Khorakiwala
Managing DirectorMurtaza Khorakiwala
Company SecretaryRashmi Mamtura
Executive DirectorHuzaifa Khorakiwala
Non Executive Independent DirectorTasneem Mehta
Vinesh Kumar Jairath
Akhilesh Gupta
Amelia Fernandes
Non Independent & Non Executive DirectorZahabiya Khorakiwala
Incorporation Year : 08-07 1999

Registered Office :

Address : D-4, M. I. D. C,Chikalthana, Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431006 .

Phone : 0240-6632222 / 6694444

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,Luxembourg, MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.